Proteins selectively killing tumor cells

European Journal of Pharmacology

Volumn 625, Issue 1-3, 2009, Pages 165-173

  Noteborn, Mathieu H M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Apoptin; Apoptosis; Cancer; E4orf4; HAMLET; Mda 7; NS1; Oncolytic virus; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; ALPHA LACTALBUMIN; APOPTIN; B RAF KINASE; BEVACIZUMAB; CISPLATIN; E1A PROTEIN; ETOPOSIDE; GEMCITABINE; INTERLEUKIN 24; METHOTREXATE; NONSTRUCTURAL PROTEIN 1; ONCOLYTIC VIRUS; PACLITAXEL; PHOSPHOPROTEIN PHOSPHATASE 2A; PLASMID DNA; PROTEIN BCL 2; PROTEIN E6; PROTEIN E7; PROTEIN P53; ROSCOVITINE; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER RESISTANCE; CLINICAL TRIAL; GENETIC ENGINEERING; H-1 PARVOVIRUS; HUMAN; LIVER TUMOR; LUNG TUMOR; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR REGRESSION; TUMOR VIRUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; ONCOLYTIC VIRUSES; PROTEINS; VIRAL PROTEINS;

EID: 71749104227     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.06.068     Document Type: Review

References (128)

1. Aits, S., Gustafsson, L., Gustafsson, M., Mossberg, A.-K., Storm, P., Trulsson, M., Svanborg, C., in press HAMLET kills tumor cells; structure, cellular targets and therapeutic agents. In: Backendorf, C., Noteborn, M.H.M., Tavassoli, M. (Eds.), Proteins killing tumour cells. Research Signpost, Kerala, India.
2. Aits S., Gustaffson L., Hallgren O., Brest P., Gustaffson M., Trulsson M., Mossberg A.K., Simon H.U., Mograbi B., and Svanborg C. HAMLET (human alpha-lactalbumin made lethal to tumor cells) triggers authophagic tumor cell death. Int. J. Cancer 124 (2009) 1008-1019
3. Angelova A.L., Aprahamian M., Grekova S.P., Hairi A., Leuchs B., Giese N.A., Dinsart C., Herrmann A., Balboni G., Rommelaere J., and Raykov Z. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin. Cancer Res. 15 (2009) 511-519
4. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 7 (2008) 1001-1012
5. Backendorf C., Visser A.E., De Boer A.G., Zimmerman R., Visser M., Voskamp P., Zhang Y.-H., and Noteborn M.H.M. Apoptin: therapeutic potential of an early sensor of carcinogenic tramsformation. Annu. Rev. Pharmacol. Toxicol. 48 (2008) 143-169
6. Bär S., Daeffler L., Rommelaere J., and Nuesch J.P.F. Vesicular egress of non-enveloped lytic parvoviruses depends on gelsolin functioning. Plos Pathol. 4 (2008) e1000126
7. Bellail A.C., Qi L., Mulligan P., Chabra V., and Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev. Recent Clin. Trials 4 (2009) 34-41
8. Ben-Israel H., Sharf R., Rechavi G., and Kleinberger T. Adenovirus E4orf4 protein downregulates MYC expression through interaction with the PP2A-B55 subunit. J. Virol. 82 (2008) 9381-9388
9. Bocangel D., Zheng M., Mhashilkar A., Liu Y., Ramesh R., Hunt K.K., and Chada S. Combinatorial synergy induced by adenoviral-mediated mda-7 and herceptin in Her-2+ breast cancer cells. Cancer Gene Ther. 13 (2006) 958-968
10. Briggs C.D., Neal C.P., Mann C.D., Steward W.P., Manson M.M., and Berry D.P. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur. J. Cancer 45 (2009) 33-47
11. Bruno P., Brinkman C.R., Boulanger M.C., Flinterman M., Klanrit P., Landry M.C., Portsmouth D., Borst J., Tavassoli M., Noteborn M., Backendorf C., and Zimmerman R.M. Family at last: highlights of the first international meeting on proteins killing tumour cells. Cell Death Differ. 16 (2009) 184-186
12. Cao J., Arulanandam R., Vultur A., Anagnostopoulou A., and Raptis L. Adenovirus E1A requires c-Ras for full neoplastic transformation or suppression of differentiation of murine preadipocytes. Mol. Carcinogen. 46 (2007) 284-302
13. Carracedo A., Baselga J., and Pandolfi P.P. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 7 (2008) 3805-3809
14. Cattaneo R., Miest T., Shashkova E.V., and Barry M.A. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat. Rev. Microbiol. 6 (2008) 529-540
15. Chien Y., and Lowe S.W. Secreting tumour suppression. Cell 132 (2008) 339-341
16. Cool, R.H., Reis, C.R., Quax, W.J., in press. Receptor-specific variants of cytokine TRAIL with improved apoptotic characteristics. In: Backendorf, C., Noteborn, M.H.M., Tavassoli, M. (Eds.), Proteins killing tumour cells. Research Signpost, Kerala, India.
17. Cornelis J.J., Lang S.I., Stroh-Dege A.Y., Balboni G., Dinsart C., and Rommelaere J. Cancer gene therapy through autonomous parvovirus-mediated gene transfer. Curr. Gene Ther. 4 (2004) 249-261
18. Damber J.E., and Aus G. Prostate cancer. Lancet 371 (2008) 1710-1721
19. Danen-van Oorschot A.A.A.M., Van der Eb A.J., and Noteborn M.H.M. The chicken anemia virus-derived protein apoptin requires activation of caspases for induction of apoptosis in human tumor cells. J. Virol. 74 (2000) 7072-7078
20. Danen-Van Oorschot A.A.A.M., Zhang Y.H., Leliveld S.R., Rohn J.L., Seelen M.C., Bolk M.W., Van Zon A., Erkeland S.J., Abrahams J.P., and Noteborn M.H.M. Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. J. Biol. Chem. 278 (2003) 27729-27736
21. Davenport R.J. Death in the balance: pro- and antiapoptotic proteins counteract each other in vivo (apoptosis). Sci. Aging Knowl. Environ. 9 (2001) nw32
22. De Smit M.H., and Noteborn M.H.M. Apoptosis-inducing proteins in chicken anemia virus and TT virus. Curr. Top. Microbiol. Immunol. 331 (2009) 131-149
23. De Villiers E.M., and Zur Hausen H. TT viruses: oncogenic or tumor-suppressive properties?. Curr. Top. Microbiol. Immunol. 331 (2009) 109-116
24. Dhomen N., and Marais R. New insight into BRAF mutations in cancer. Curr. Opin. Genet. Dev. 17 (2007) 31-39
25. Di Piazza M., Mader C., Geletneky K., Herrero Y., Calle M., Weber E., Schlehofer J., Deleu L., and Rommelaere J. Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J. Virol. 81 (2007) 4186-4198
26. Düringer C., Hamiche A., Gustafsson L., Kimura H., and Svanborg C. HAMLET interacts with histones and chromatin in tumor cell nuclei. J. Biol. Chem. 278 (2003) 42131-42135
27. Eager R., Harle L., and Nemunaitis J. Ad-mda-7; INGN241: a review of preclinical and clinical experience. Expert Opin. Biol. Ther. 8 (2008) 1633-1643
28. Ekmekcioglu S., Mumm J.B., Udtha M., Chada S., and Grimm E.A. Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24. Cytokine 43 (2008) 34-44
29. Emdad L., Lebedeva I.V., Su Z.Z., Gupta P., Sauane M., Dash R., Grant S., Dent P., Curiel D.T., Sarkar D., and Fisher P.B. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumour properties of mda-7/IL-24. Cancer Biol. Ther. 8 (2009) 391-400
30. Fan Y., and Bergmann A. Apoptosis-induced compensatory proliferation. The cell is dead. Long live the cell. Trends Cell Biol. 18 (2008) 467-473
31. Fast J., Mossberg A.K., Nilsson H., Svanborg C., Akke M., and Linse S. Compact oleic acid in HAMLET. FEBS Lett. 579 (2005) 6095-6100
32. Festa M., Petrella A., Alfano S., and Parente L. R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway. Int. J. Cancer (2009) 2728-2736
33. Fisher P.B., Sarkar D., Lebedeva I.V., Emdad, Gupta P., Sauane M., Su Z.Z., Grant S., Dent P., Curiel D.T., Senzer N., and Nemunaitis J. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol. Appl. Pharmacol. 224 (2007) 300-307
34. Flinterman M., Farzaneh F., Habib N., Malik F., Gaken J., and Tavassoli M. Delivery of therapeutic proteins as secretable TAT fusion products. Mol. Ther. 17 (2009) 334-342
35. Fuster J.J., Sanz-Gonzalez S.M., Moll V.M., and Anders V. Classic and novel roles of p53: prospects for anti-cancer therapy. Trends Mol. Med. 13 (2007) 192-199
36. Gingras M.-C., Champagne C., Roy M., and Lavoie J.N. Cytoplasmic death signal triggered by Src-mediated phosphoryaltion of the adenovirus E4orf4 protein. Mol. Cell. Biol. 22 (2002) 41-56
37. Giovanetti A., Pierdominici M., Di Iorio A., Cianci R., Murdaca G., Puppo F., Pandolfi F., and Paganelli R. Apoptosis in the homeostasis of the immune system and in human immune mediated diseases. Curr. Pharm. Des. 14 (2008) 253-268
38. Gonzalez-Angulo A.M., Morales-Vasquez F., and Hortobagyi G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 608 (2007) 1-22
39. Gopalan B., Shanker M., Chada S., and Ramesh R. Mda-7/IL-24 suppresses human ovarian carcinoma growth in vitro and in-vivo. Mol. Cancer 6 (2007) 11
40. Grinstein E., and Wernet P. Cellular signaling in normal and cancerous stem cells. Cell. Signal. 19 (2007) 2428-2433
41. Guelen L., Paterson H., Gaken J., Meyers M., Farzaneh F., and Tavassoli M. TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene 23 (2004) 1153-1165
42. Hall M.A., and Cleveland J.L. Clearing the TRAIL for cancer therapy. Cancer Cell 12 (2007) 4-6
43. Hallgren O., Aits S., Brest P., Gustafsson L., Mossberg A.K., Wullt B., and Svanborg C. Apoptosis and tumor cell death in response to HAMLET (human alpha-lactalbumin made lethal to tumor cells). Adv. Exp. Med. Biol. 606 (2008) 217-240
44. Haseley A., Alvarez-Breckenridge C., Chaudhury A.R., and Kaur B. Advances in oncolytic virus therapy for glioma. Recent Pat. CNS Drug Discov. 4 (2009) 1-13
45. Heilman D.W., Green M.R., and Teodoro J.G. The anaphase promoting complex: a critical target for viral proteins and anti-cancer drugs. Cell Cycle 4 (2005) 560-563
46. Heilman D.W., Teodoro J.G., and Green M.R. Apoptin nucleocytoplasmic shuttling is required for cell-type specific localization, apoptosis, and recruitment of the anaphase-promoting complex/cyclosome to PML bodies. J. Virol. 80 (2006) 7535-7545
47. Howie H.L., Katzenellenbogen R.A., and Galloway D.A. Papillomavirus E6 proteins. Virology 384 (2009) 324-334
48. Høyer-Hansen M., and Jäättelä M. Autophagy: an emerging target for cancer therapy. Autophagy 1 (2008) 574-580
49. Iannolo G., Conticello C., Memeo L., and De Maria R. Apoptosis in normal and cancer stem cells. Crit. Rev. Oncol. Hematol. 66 (2008) 42-51
50. Inoue S., Hartman A., Branch C.D., Bucana C.D., Bekele B.N., Stephens L.C., Chada S., and Ramesh R. Mda-7 in combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. Mol. Ther. 15 (2007) 287-294
51. Johnstone R.W., Frew A.J., and Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 8 (2008) 782-798
52. Kamada K., Kuroishi A., Kamahora T., Kabat, Yamaguchi S., and Hino S. Spliced mRNAs detected during the life cycle of chicken anemia virus. J. Gen. Virol. 87 (2006) 2227-2233
53. Kirn D.H., and Thorne S.H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer 9 (2009) 64-71
54. Klanrit P., Flinterman M.B., Odell E.W., Melino G., Killick R., Norris J.S., and Tavassoli M. Specific isoforms of p73 control the induction of cell death induced by the viral proteins, E1A or apoptin. Cell Cycle 15 (2008) 205-215
55. Köhler C., Gogvadze V., Häkansson A., Svanborg C., Orrenius S., and Zhivotovsky B. A folding variant of human alpha-lactalbumin induces mitochondrial permeability transition in isolated mitochondria. Eur. J. Biochem. 268 (2001) 186-191
56. Kooistra K., Zhang Y.H., Henriquez N.V., Weiss B., Mumberg D., and Noteborn M.H.M. TT virus-derived apoptosis-inducing protein induces apoptosis preferentially in hepatocellular carcinoma-derived cells. J. Gen. Virol. 85 (2004) 1445-1450
57. Kumar S., Gao L., Yeaggy B., and Reid T. Virus combinations and chemotherapy for the treatment of human cancers. Curr. Opin. Mol. Ther. 10 (2008) 371-379
58. LaCasse E.C., Mahoney D.J., Cheung H.H., Plenchette S., Baird S., and Korneluk R.G. IAP-targeted therapies for cancer. Oncogene 27 (2008) 6252-6275
59. Lachmann S., Bär S., Rommelaere J., and Nuesch J.P. Parvovirus interference with intracellular signalling: mechanism of PKCeta activation in MVM-infected A9 fibroblasts. Cell Microbiol. 10 (2008) 755-769
60. Landry M.C., Robert A., and Lavoie J.N. Alternative cell death pathways: lessons learned from a viral protein. Bull. Cancer 93 (2006) 921-930
61. Lavoie J.N., Champagne C., Gingras M.C., and Robert A. Adenovirus E4 open reading frame 4-induced apoptosis involves dysregulation of Src family kinase. J. Cell Biol. 150 (2000) 1037-1056
62. Lebedeva I.V., Emdad L., Su Z.Z., Gupta P., Sauane M., Sarkar M.R., Staudt M.R., Liu S.J., Taher M.M., Xiao R., Barral P., Lee S.G., Wang D., Vozhilla N., Park E.S., Chatman L., Boukerche H., Ramesh R., Inoue S., Chada S., Li R., De Pass A.L., Mahareseshti P.J., Dmitriev I.P., Curiel D.T., Yacoub A., Grant S., Dent P., Senzer N., Nemunaitis J.J., and Fisher P.B. mda-7/IL-24, a novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience. Int. J. Oncol. 31 (2007) 985-1007
63. Lessene G., Czabotar P.E., and Colman P.M. Bcl-2 family antagonists for cancer therapy. Nat. Rev. Drug Discover. 7 (2008) 989-1000
64. Levine A.J. The common mechanisms of transformation by the small DNA tumor viruses: the inactivation of tumor suppressor gene products: p53. Virology 384 (2009) 285-293
65. Levine B., Sinha S., and Kroemer G. Bcl-2 family members. Autophagy 4 (2008) 600-606
66. Li S., Szymborski A., Miron M.J., Marcellus R., Binda O., Lavoie J.N., and Branton P.E. The adenovirus E4orf4 protein induces growth arrest and mitotic catastrophe in H1299 human lung carcinoma cells. Oncogene 28 (2009) 390-400
67. Lin J., Lai M., Huang Q., Ruan W., Ma Y., and Cui J. Reactivation of IGFBP7 by DNA methylation inhibits human colon cancer cell growth in vitro. Cancer Biol. Ther. 7 (2008) 1896-1900
68. Liu X., Elojeimy S., El-Zawahry A.M., Holman D.H., Bielawska A., Bieliwski J., Rubinchik S., Guo G.W., Dong J.Y., Keane T., Hannun Y.A., Tavassoli M., and Norris J.S. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol. Ther. 14 (2006) 637-646
69. Liu X., Zeidan Y.H., Elojeimy S., Holman D.H., El-Zawahry A.M., Guo G.W., Bielawska A., Bielawski J., Szulc Z., Rubinchik S., Dong J.Y., Keane T.E., Tavassoli M., Hannun Y.A., and Norris J.S. Involvement of sphingolipids in apoptin-induced cell killing. Mol. Ther. 14 (2006) 627-636
70. Liu Q., Fu H., Xing R., Tie Y., Zhu J., Sun Z., and Zheng X. Survivin knockdown combined with apoptin over-expression inhibits cell growth significantly. Cancer Biol. Ther. 7 (2008) 1053-1060
71. Maddika S., Booy E.P., Johar D., Gibson S.B., Ghavami S., and Los M. Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a NUR-77 pathway. J. Cell Sci. 118 (2005) 4485-4493
72. Maddika S., Mendoza F.J., Hauff K., Zamzow C.R., Paranjothy T., and Los M. Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol. Ther. 5 (2006) 10-19
73. Maddika S., Panigrahi S., Wiechec E., Wesselborg S., Fischer U., Schulze-Osthoff, and Los M. Unscheduled Akt-triggered activation of CDK2 as a key effector mechanism of apoptin's anticancer toxicity. Mol. Cell Biol. 29 (2009) 1235-1248
74. Mahalingam D., Szegezdi E., Keane M., De Jong S., and Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL?. Cancer Treat. Rev. 35 (2008) 280-288
75. Mishra L., Banker T., Murray J., Byers S., Thenappan A., He A.R., Shetty K., Johnson L., and Reddy E.P. Liver stem cells and hepatocellular carcinoma. Hepatology 49 (2009) 318-329
76. Mitrus I., Missol-Kolka E., Plucienmiczak A., and Szala S. Tumour therapy with genes encoding apoptin and E4orf4. Anticancer Res. 25 (2005) 1087-1090
77. Mossberg A.-K., Wullt B., Gustafsson L., Mansson W., Ljunggren E., and Svanborg C. Bladder cancers respond to intravesical instillation of HAMLET (human α-lactalbumin made lethal to tumor cells). Int. J. Cancer 121 (2007) 1352-1359
78. Murray-Zmijewski F., Slee E.A., and Lu X. A complex barcode underlies the heterogenous response of p53 to stress. Nat. Rev. Mol. Cell. Biol. 9 (2008) 702-712
79. Newson-Davis, Prieske S., and Walczak H. Is TRAIL the holy grail of cancer therapy?. Apoptosis 14 (2009) 607-623
80. Noteborn M.H.M. Apoptin acts as a tumor-specific killer: potentials for an anti-tumor therapy. Cell Mol. Biol. 51 (2005) 49-60
81. Noteborn, M.H.M, in press. Apoptosis and cancer closely linked. In: Backendorf, C., Noteborn, M.H.M., Tavassoli, M. (Eds.), Proteins killing tumour cells. Research Signpost, Kerala, India.
82. Nuesch J.P.F., and Rommelaere J. NS1 interaction with CKIIα: novel protein complex mediating parvovirus-induced cytotoxicity. J. Virol. 80 (2006) 4729-4739
83. Nuesch J.P.F., and Rommelaere J. A viral adaptor modulating casein kinase II activity induces cytopathic effects in permissive cells. Proc. Natl. Acad. Sci. 104 (2007) 12482-12487
84. Nuesch J.P.F., Bär S., and Rommelaere J. Viral proteins killing tumor cells. Cancer Biol. Ther. 7 (2008) 1-3
85. Nuesch J.P.F., Bär S., Lachmann S., and Rommelaere J. Ezrin-radixin-moesin family proteins are involved in parvovirus replication and spreading. J. Virol. 83 (2009) 5854-5863
86. Olijslagers S., Dege A.Y., Dinsart C., Voorhoeve M., Rommelaere J., Noteborn M.H.M., and Cornelis J.J. Potentiation of a recombinant oncolytic parvovirus by expression of apoptin. Cancer Gene Ther. 2001 8 (2001) 958-965
87. Olijslagers S., Zhang Y.-H., Backendorf C., and Noteborn M.H.M. Additive effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells. Basic Pharm. Tox. 100 (2007) 127-131
88. Olopade O.I., Grushko T.A., Nanda R., and Huo D. Advances in breast cancer: pathways to personalized medicine. Clin. Cancer Res. 14 (2008) 7988-7999
89. Peng D., Sun J., Wang Y.-Z., Tian J., Zhang Y.-H., Noteborn M.H.M., and Qu S. Inhibition of hepatocarcinoma by systemic delivery of apoptin gene via the hepatic asialoglycoprotein receptor. Cancer Gene Ther. 14 (2007) 66-73
90. Permyakov S.E., Pershikova I.V., Zhadan A.P., Goers J., Bakunts A.G., Uversky V.N., Berliner L.J., and Permyakov E.A. Conversion of human alpha-lactalbumin to an apo-like state in the complexes with basic poly-amino acids: toward understanding of the molecular mechanism of antitumor action of HAMLET. J. Proteome Res. 4 (2005) 564-569
91. Prestwich R.J., Harrington K.J., Pandha H.S., Vile R.G., Melcher A.A., and Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev. Anticancer Ther. 8 (2008) 1581-1588
92. Qiao L., and Wong B.C.Y. Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drug Resist. Upd. 9 (2009) Electronic publication ahead of print
93. Qu, S., Noteborn, M.H.M., in press. Preclinical studies on apoptin unravels its specific anticancer therapy potential. In: Backendorf, C., Noteborn, M.H.M., Tavassoli, M. (Eds.), Proteins killing tumour cells. Research Signpost, Kerala, India.
94. Raykov Z., Grekova S., Galabov A.S., Balboni G., Koch U., Aprahamian M., and Rommelaere J. Combined oncolytic and vaccination activities of parvovirus-H1 in a metastatic tumor model. Oncol. Rep. 17 (2007) 1493-1499
95. Riley T., Sontag E., Chen P., and Levine A. Transcriptional control of human p53 regulated genes. Nat. Rev. Mol. Cell Biol. 9 (2008) 402-412
96. Rohn J.L., and Noteborn M.H.M. The viral death effector apoptin reveals tumor-specific processes. Apoptosis 9 (2004) 315-322
97. Rohn J.L., Zhang Y.-H., Aalbers R.I., Otto N., Den Hertog J., Henriquez N.V., Van de Velde C.J., Kuppen P.J., Mumberg D., Donner P., and Noteborn M.H.M. A tumor-specific kinase activity regulates the viral death protein Apoptin. J. Biol. Chem. 277 (2002) 50820-50827
98. Rohn J.L., Zhang Y.H., Leliveld S.R., Danen-van Oorschot A.A.A.M., Henriquez N.V., Abrahams J.P., and Noteborn M.H.M. Relevance of apoptin's integrity for its functional behavior. J. Virol. 79 (2005) 1337-1338
99. Ruan W., Xu E., Xu F., Ma Y., Deng H., Huang Q., Lv B., Hu H., Lin J., Cui J., Di M., Dong J., and Lai M. IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biol. Ther. 6 (2007) 354-359
100. Russell S.J., and Peng K.W. The utility of cells as vehicles for oncolytic virus therapies. Curr. Opin. Mol. Ther. 10 (2008) 380-386
101. Russo A., Terrasi M., Agnese V., Santini D., and Bazan V. Apoptosis: a relevant tool for anticancer therapy. Ann. Oncol. Suppl. 7 (2006) vii 115-vii 123
102. Salvesen G.S., and Riedl S.J. Caspase mechanisms. Adv. Exp. Med. Biol. 615 (2008) 13-23
103. Sanchez-Munoz A., Perez-Ruiz E., Ribelles N., Marquez A., and Alba E. Maintenance treatment in metastatic breast cancer. Expert Rev. Anticancer Ther. 8 (2008) 1907-1912
104. Sarkar D., Dent P., Curiel D.T., and Fisher P.B. Acquired and innate resistance to the cancer-specific apoptosis-inducing cytokine mda-7: not insurmountable therapeutic problems. Cancer Biol. Ther. 7 (2008) 109-112
105. Scarlatti F., Granata R., Meijer A.J., and Codogno P. Does autophagy have a license to kill mammalian cells?. Cell Death Differ. 16 (2009) 12-120
106. Schaffhausen B.S., and Roberts T.M. Lessons from polyoma middle T antigen on signalling and transformation: a DNA tumor virus contribution to the war on cancer. Virology 384 (2009) 304-316
107. Schoop, R.A. 2009. Apoptin gene therapy for head and neck cancer. PhD Thesis, Leiden University, Leiden, the Netherlands.
108. Schoop R.A., Kooistra K., Baatenburg De Jong R.J., and Noteborn M.H.M. Bcl-xL inhibits p53- but not apoptin-induced apoptosis in head and neck squamous cell carcinoma cell line. Int. J. Cancer 109 (2004) 38-42
109. Shtrichman R., Sharf R., Barr H., Dobner T., and Kleinberger T. Induction of apoptosis by adenovirus E4orf4 protein is specific to transformed cells and requires an interaction with protein phosphatase 2A. Proc. Natl. Acad. Sci. 96 (1999) 10080-10085
110. Shulman-Peleg A., Shatsky M., Nussinov R., and Wolfson H.J. Spatial chemical conversation of hot-spot interactions in protein-protein complexes. BMC Biol. 5 (2007) 43
111. Smadja-Lamere R.A., Landry M.C., Champagne C., Petrie R., Lamarche-Vane N., Hosoya H., and Lavoie J.N. Adenovirus E4orf4 hijacks rho GTPase-dependent actin dynamics to kill cells: a role for endosome-associated actin assembly. Mol. Biol. Cell 17 (2006) 3329-3344
112. Soussi T., and Wyman K.G. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Oncogene 26 (2007) 2177-2184
113. Su Z.Z., Lebedeva I.V., Sarkar D., Emdad L., Gupta P., Kitada S., Dent P., Reed J.C., and Fisher P.B. Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL24 resistance in prostate cancer cells over-expressing the anti-apoptotic proteins Bcl-xL or Bcl-2. Oncogene 25 (2006) 2339-2348
114. Sun J., Yan Y., Wang X.-T., Liu X.-W., Peng D., Wang M., Tian J., Zong Y.-Q., Zhang Y.-H., Noteborn M.H.M., and Qu S. PTD4-apoptin protein therapy inhibits tumor growth in vivo. Int. J. Cancer 124 (2009) 2973-2981
115. Svensson M., Hakansson A., Mossberg A.K., Linse S., and Svanborg C. Conversion of alpha-lactalbumin to a protein inducing apoptosis. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 4221-4226
116. Syrigos K.N., Zalonis A., Kotteas E., and Saif M.W. Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev. 27 (2008) 273-288
117. Tanaka S., and Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci. 100 (2009) 1-8
118. Thomas M., Narayan N., Pim D., Tomaic V., Massimi P., Nagasaka K., Kranjec C., Gammoh N., and Banks L. Human papillomaviruses, cervical cancer and cell polarity. Oncogene 27 (2008) 7018-7030
119. Tusell L., Soler D., Agostini M., Pampalona J., and Genesca A. The number of dysfunctional telomeres in a cell: one amplifies; more than one translocate. Cytogenet. Genome Res. 122 (2008) 315-325
120. Vähä-Koskela M.J.V., Heikkila J.E., and Hinkkanen A.E. Oncolytic viruses in cancer therapy. Cancer Let. 254 (2007) 178-216
121. Vazquez A., Bond E.A., Levine A.J., and Bond G.L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discover. 7 (2008) 979-987
122. Virshup D.M., and Shenolikar S. From promiscuity to precision: protein phosphatases get a makeover. Mol. Cell 33 (2009) 537-545
123. Visser A.E., Backendorf C., and Noteborn M.H.M. Viral protein apoptin as a modulator tool and therapeutic bullet: implications for cancer control. Future Virol. 2 (2007) 519-527
124. Wajapeyee N., Serra R.W., Zhu X., Mahalingam M., and Green M.R. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132 (2008) 363-374
125. Whibley C., Pharoah P.D., and Hollstein M. p53 polymorphisms: cancer implications. Nat. Rev. Cancer 9 (2009) 95-107
126. White E. Mechanisms of apoptosis regulation by viral oncogenes in infection and tumorigenesis. Cell Death Diff. 13 (2006) 1371-1377
127. Zhang Y.-H., Kooistra K., Pietersen A.M., Rohn J.L., and Noteborn M.H.M. Activation of the tumor-specific death effector apoptin and its kinase by an N-terminal determinant of Simian Virus 40 large T antigen. J. Virol. 78 (2004) 9965-9976
128. Zhuang S.M., Shvarts A., Van Ormondt H., Jochemsen A.G., Van der Eb A.J., and Noteborn M.H.M. Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells. Cancer Res. 55 (1995) 486-489